关于盟科
公司简介
公司团队
愿景与使命
发展历程
联系我们
科学研究
抗生素耐药性
肾病靶向治疗
盟科研发模式
发表文献
研发管线
新闻中心
新闻发布
加入我们
联系我们
En
科学研究
以良药求良效。
首页
发表文献
抗生素耐药性
肾病靶向治疗
盟科研发模式
发表文献
A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections
J Antimicrob Chemother / 2022
View Publication
Contezolid: First Approval
Drugs / 2021
View Publication
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
Antimicrob Agents Chemother / 2021
View Publication
Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity
Chem Res Toxicol / 2021
View Publication
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Antimicrob Agents Chemother / 2020
View Publication
Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers
Antimicrob Agents Chemother / 2020
View Publication
Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent,in Chinese Patients
Clinical Therapeutics / 2020
View Publication
Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis
Clinical Therapeutics / 2019
View Publication
Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
J Pharmacokinet Pharmacodyn / 2019
View Publication
Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
Clinical Therapeutics / 2018
View Publication
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis
Antimicrob Agents Chemother / 2018
View Publication
Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I Versus Linezolid in Healthy Adult Subjects
Antimicrob Agents Chemother / 2017
View Publication
1
2
>
关闭